diabetestalk.net

Novo Nordisk Diabetes Educator Program

Director, Marketing Diabetes Education Program

Director, Marketing Diabetes Education Program

Director, Marketing Diabetes Education Program 11 - 15 years experience Biotech/Pharma Develops the Diabetes Education Program short term and long term strategy and tactics with the overarching objectives to develop and shape the market through efficient Population Health Management dialogue with Healthcare Professionals. Ensures that Healthcare Professional initiatives are prioritized to optimize impact across the diabetes portfolio. Ensures that targeting and goals are optimally aligned to strategy. Position reports to the Senior Director/Vice President in Commercial Operations. Works closely with brand marketing, Circle of Excellence, managed market strategy, field sales, medical, legal and compliance groups to achieve business objectives. Serves in a central leadership role to optimize market development and market shaping efforts across the portfolio. External relationships include Key Opinion Leaders, Health System executives, associations, vendors and consultants. Develop strategy and tactics in alignment and collaboration with key marketing and field stakeholders. Oversees project management which includes defining deliverables, structuring, problem solving, prioritizing, work planning, communicating, implementation and tracking. Coordinates with key support groups/accounts to develop educational programs that support the brand objectives and goals. Optimize spends and ensure that resources are appropriately developed, allocated and quality of services are maintained. Oversees contract management. Ensures expense are tracked and reconciled to ensure budget remains on track. Responsible for the oversight of Diabetes Education Program budget to target levels. COORDINATION/COMMUNICATION AND ADMINISTRATION: Create DEP internal marketing strategies that support Diab Continue reading >>

Adea | Novo Nordisk

Adea | Novo Nordisk

Novo Nordisk is a focused health care company and a world leader in diabetes care. Our strong commitment to changing diabetes is reflected in our focus on research and development, our partnerships with professional and consumer organisations and our commitment to communities in the developing world through the World Diabetes Foundation. This commitment is reflected in both our sustaining membership, and our business partnership with the ADEA. Under the Business Partnership Program, Novo Nordisk is pleased to provide financial support for the Novo Nordisk-ADEA Diabetes Educators Graduate Scholarship Program . Scholarships are available to provide financial assistance to two members of the ADEA that have successfully completed an ADEA Accredited course during the current year. The aim of these scholarships is to increase the capacity of health service providers across Australia in the provision of high quality diabetes self-management education services. ADEA also partnered with NovoNordisk to undertake theDiabetes Referral Map project. This project was to design a referral framework within primary care and across primary and tertiary care that builds on identified existing best practice models that are transferable to other various practice and geographic environments. Keep up to date. Subscribe to ADEA newsletter. Continue reading >>

Novo Nordisk Diabetes Education Program Receives Ncqa Disease Management Certification In Program Design

Novo Nordisk Diabetes Education Program Receives Ncqa Disease Management Certification In Program Design

Novo Nordisk Diabetes Education Program Receives NCQA Disease Management Certification in Program Design Certification demonstrates Novo Nordisk's commitment to improving diabetes care Oct 23, 2014, 10:00 ET from Novo Nordisk PLAINSBORO, N.J., Oct. 23, 2014 /PRNewswire/ --Novo Nordisk, a global leader in diabetes care, was honored with The National Committee for Quality Assurance (NCQA)'s Disease Management Certification in Program Design for its Diabetes Education Program (DEP) this month. The 2-year certification validates the DEP as a program providing quality educational support to both health care providers and patients that meets the rigorous review of the NCQA Disease Management Program Design standards. It also demonstrates the DEP's commitment to continuously enhance the quality of the program and Novo Nordisk's commitment to improve diabetes care. NCQA Disease Management Certification standards are intended to help organizations achieve the highest level of performance possible, reduce patient risk and create an environment of continuous improvement. These standards build on NCQA's years of accreditation and certification experience, detailed market research and input from industry experts and other stakeholders. The DEP was evaluated on 68 program elements within five categories, which included evidence-based guidelines, patient services, provider programs, program marketing and operations and measurement of quality improvement efforts. "Novo Nordisk is proud to receive the NCQA Disease Management Certification in Program Design," said Patricia Bradley, DEP Vice President, Diabetes Marketing. "The process was a rigorous evaluation of our entire DEP program and our approach to disease management. This certification underscores Novo Nordisk's commitment to pro Continue reading >>

Novo Nordisk Has Been Accused Of Engaging In A 'white Coat Marketing Scheme' To Sell Diabetes Drugs

Novo Nordisk Has Been Accused Of Engaging In A 'white Coat Marketing Scheme' To Sell Diabetes Drugs

Danish pharmaceutical giant Novo Nordisk is being accused of engaging in a "white coat marketing scheme" to entice doctors to prescribe three of its diabetes drugs — NovoLog, Levimir, and Victoza. Together these three drugs made Novo Nordisk $6 billion in sales in 2013, comprising 10% of the company's worldwide sales for the year, according to the complaint. Specifically, whistleblowers allege that the company illegally hired Certified Diabetes Educators (CDEs) and employed them as sales reps, and then sent them into doctors offices to promote the drug through its "Changing Life with Diabetes Program." The suit claims that, because the company's sales reps were titled as CDEs, they got unprecedented access to doctors. However, "they were sales representatives in every way except title." Once inside the CDE's allegedly educated doctors for free. Novo Nordisk, for its part, is a member of the powerful PhRMA lobby, which prohibits member companies from exchanging free medical education for prescriptions. The government is jumping in because these drugs are all covered by federal health insurance programs — Medicaid, Medicare, and Tricare. And t he suit could be a sign that, in an effort to reduce costs, the government is focusing on its reimbursement of drugs. Novo Nordisk has responded to Business Insider's request for comment with the following statement: “In February 2011, the U.S. Attorney’s Office for the District of Massachusetts served Novo Nordisk with a subpoena calling for the production of documents regarding potential civil and criminal offences relating to the company’s marketing and promotional practices for the following products: NovoLog®, Levemir® and Victoza®. This matter is being conducted by the US Attorney for the District of Columbia. We Continue reading >>

Novo Nordisk Diabetes Educator - Shreveport, La In Shreveport, La

Novo Nordisk Diabetes Educator - Shreveport, La In Shreveport, La

Changing diabetes. It's a challenge that affects the lives of hundreds of millions of people worldwide. Novo Nordisk is the world leader in diabetes research, care and treatment, and our passion for helping people is at the heart of everything we do. But our ability to change lives depends on delivering the latest information about diabetes treatment and management to the healthcare community. That's why we're looking for the best of the best to join our diabetes education team. As a Diabetes Educator at Novo Nordisk, you'll have the opportunity to take your love of diabetes education to the next level - training a wide range of healthcare providers and their staffs, building customized training approaches and materials, and acting as a strategic partner to the hundreds of thousands of doctors we work with each year. And with our competitive compensation and benefits, and an industry-leading training and development curriculum, you'll quickly see why Novo Nordisk is repeatedly recognized as one of the best places to work. If you share our passion for changing lives, and believe you have the expertise to effectively deliver life-changing information to healthcare providers, we invite you browse the open positions below, and apply to one that fits your interests, skills and geographic location. To get started, please choose the Diabetes Educator job that is right for you and join the Novo Nordisk Talent Community. Once you join, please Apply Online at: Requisition ID 7537BR Title Diabetes Educator - Shreveport LA Job Category Field Education Job Description Diabetes Educator Job Description: The field based Diabetes Educator is responsible for assessing, implementing and evaluating Diabetes Education based on ADA Standards of care. Educate primary care providers, special Continue reading >>

Novo Nordisk: Stop Diabetes American Diabetes Association

Novo Nordisk: Stop Diabetes American Diabetes Association

Novo Nordisk supports the Stop Diabetes movement and the Association's mission in research, advocacy and education. The company supports the American Diabetes Association and Novo Nordisk Awards in Hypoglycemia in Diabetes as well as the American Diabetes Association and Novo Nordisk Awards in Neurohormonal Control of Metabolism. In addition, Novo Nordisk is also a founding sponsor of the Association's new research program Pathway To Stop Diabetes and supports our legal advocacy activities to prevent discrimination against people with diabetes. To support patient education, the company also supports Diabetes EXPO as a national sponsor and is the National Premier Sponsor of Step Out: Walk to Stop Diabetes. As a National Red Strider sponsor of Step Out, Novo Nordisk is encouraging people with diabetes to live a healthier lifestyle. To learn more, visit www.novonordisk-us.com Stop Diabetes is the Association's movement to end the devastating toll that diabetes takes on the lives of millions of individuals and families across our nation. Join the Millions in the Movement. Together we can Stop Diabetes. Continue reading >>

Healing In Houston Through Faith And Diabetes

Healing In Houston Through Faith And Diabetes

Healing in Houston Through Faith and Diabetes An innovative program in Houston empowers members of faith communities to lead diabetes education, peer support, and prevention efforts in their communities When considering a typical diabetes care team, a few key individuals may jump to mind a doctor, nurse, pharmacist, diabetes educator, dietitian or nutritionist, and perhaps a physical therapist and a few other healthcare professionals. Who is left out of this picture? Your faith leader and you, says Ardis A. Reed, a Certified Diabetes Educator (CDE) from TMF Health Quality Institute, Austin, Texas and one of the main facilitators of the Faith and Diabetes Initiatives Congregational Health Leadership training program. By integrating faith into diabetes awareness and support, the Faith and Diabetes Initiative in Houston adds a new twist to the traditional diabetes care team. Lay members of various religious communities are trained to provide an evidence-based diabetes education curriculum, peer support, and prevention programs in their houses of worship, whether churches, mosques, synagogues or temples. The inaugural class graduated from this training program this month in Houston, with graduates sharing their plans to kick off diabetes support and management programs in their respective congregations and faith communities. The Faith and Diabetes Initiative is part of Cities Changing Diabetes (CCD) a program of Novo Nordisk that supports diabetes awareness, care, education, and prevention in twelve partner cities around the world. Houston, where over 30% of adults are affected by obesity and 15.6% have diabetes , was a natural choice to be CCDs partner city in the US. With sprawling highways, limited public transportation, and a fast food density higher than the state of Continue reading >>

Novo Nordisk Announces Free Diabetes Educational E-book Series

Novo Nordisk Announces Free Diabetes Educational E-book Series

Novo Nordisk announces free diabetes educational e-book series Today, Novo Nordisk, a world leader in diabetes care, launched a free 5-volume diabetes educational e-book series, designed to help patients work with their health care team to better manage their diabetes. The e-book series is part of Cornerstones4Care, an innovative patient support program that provides highly customizable diabetes information through the comprehensive interactive website www.Cornerstones4Care.com . Novo Nordisk is committed to helping patients achieve their diabetes goals and saw a need to make diabetes management information more accessible. According to the Association of American Publishers, as of February 2011 e-books ranked as the number one selling format among all categories of trade publishing and sales are continuing to increase. New research program receives DKK 100 million in funding from Novo Nordisk Foundation "With an increasing demand for e-books, we saw an opportunity to share our existing diabetes education book series in a new and innovative format that meets the changing technology needs of today's patient," said Camille Lee, Corporate Vice President, Diabetes Marketing. "By broadening the availability of the educational series, we hope that more patients will have access to the resources they need to better manage their diabetes." The first e-book, Diabetes and You, is available on Cornerstornes4Care.com and will be available at popular e-book sites, including iBooks, Reader Store, the NOOK Book Store and Free-eBooks.net beginning Q4 2011. The entire e-book series is also compatible with all major e-readers, including Apples iPad, Sonys e-Reader, Barnes & Nobles NOOK and Amazons Kindle. Those who might not have an e-reader can download the e-book series for free as an Continue reading >>

Novo Settles U.s. Probe Of Kickbacks, Disguised Salespeople

Novo Settles U.s. Probe Of Kickbacks, Disguised Salespeople

Unsealed whistle-blower suit outlines illegal marketing claims Diabetes drugs made up 80 percent of Novo’s 2016 revenue Novo Nordisk A/S has agreed to settle a U.S. probe of its marketing of diabetes drugs that allegedly included disguising salespeople as medical educators and paying kickbacks to persuade doctors to prescribe its medicines. The allegations were disclosed when a whistle-blower lawsuit was unsealed by a judge. The U.S. Justice Department investigation, which began in 2011, focused on claims of illegal marketing of the Danish insulin supplier’s top-selling Victoza diabetes drug and other products, according to Novo’s 2016 annual report. “We’ve reached an agreement in principle to settle certain claims related to this investigation,” Ken Inchausti, a U.S.-based spokesman for Novo, said in an emailed statement Friday. “The process is not finalized, and as such we can’t provide further comment on this matter at this time.” Inchausti said the whistle-blower suit was unsealed Thursday as part of the settlement. Nicole Navas, a DOJ spokeswoman, didn’t immediately return a call and email seeking comment on the Novo accord. The suit was filed by two whistle-blowers who claimed the company violated U.S. law by wrongfully inducing doctors to write prescriptions for Victoza that were covered by federal health-insurance programs. The lawsuit targeted Bagsvaerd, Denmark-based Novo’s key products. Diabetes treatments accounted for almost 80 percent of the company’s 111.78 billion kroner ($16.3 billion) of revenue in 2016. The drug sales have increased more than 75 percent in the past five years, rising to 88.95 billion kroner in 2016 from 50.43 billion in 2011. Since 2006, Novo officials have “engaged in an unlawful marketing and kickback schem Continue reading >>

Novo Education Exchange Supports In Optimal Diabetes Management | Ndei

Novo Education Exchange Supports In Optimal Diabetes Management | Ndei

Education Exchange Online, Hosted on NDEI.org, Supports Healthcare Professionals in Optimal Diabetes Management New Diabetes Education Website Supported by Novo Nordisk SEPTEMBER 19, 2013: NDEI.org , the official website of The National Diabetes Education Initiative (NDEI), announces the launch of Education Exchange Online, a new website offering educational programs designed to support healthcare professionals in the optimal management of diabetes. Available at EducationExchangeHCP.org , the website is supported by Novo Nordisk. Education Exchange Online is a cohesive digital education platform that presents a full range of interactive programming and content. Diabetes healthcare professionals are invited to view on-demand offerings, including video presentations with key diabetes opinion leaders, clinical information about the Novo Nordisk portfolio of diabetes products, and links to diabetes education resources. Exclusive access to registration opportunities for Novo Nordisk live diabetes programs and events, including the Exchange Online Diabetes Seminar Series, a succession of live webconference programs covering diabetes epidemiology, pathophysiology, and management considerations, is also provided. Headquartered in Denmark, Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions with hemophilia care, growth hormone therapy, and hormone replacement therapy. For more information, visit www.novonordisk.com . NDEI.org is a premier, award-winning destination for diabetes education that augments knowledge and practice gaps among healthcare professionals with the goal of enhancing patient care. The website unites more than 40,000 registered members who enjoy premium content offering Continue reading >>

Educational Materials For Your Patients

Educational Materials For Your Patients

Curated for the diabetes care partner, this set provides basic information about diabetes, clarifies the partner's role in caring for someone with the disease, and explains the importance of taking good care of themselves. Continue reading >>

Novo Nordisk Settles Qui Tam Suit

Novo Nordisk Settles Qui Tam Suit

Novo Nordisk is in the midst of settling a whistleblower lawsuit that alleges that the company ran a white-coat marketing scheme to pump up sales of NovoLog, Victoza, and Levemir. The complaint was recently unsealed as part of the settlement process and alleges that Novo Nordisk partnered up with a clinical education company, Healthstars PT, to set up a program Changing Life with Diabetes which hired and trained certified diabetes educators. The whistleblowers, two former managers, claim that since 2006, Novo ran the program to gain access to physician practices, where the educators would provide thousands of dollars worth of educational programs and materials, including: free patient education and seminars; free in-office training; free Novo-branded log books to give patients; and unlimited access to go to diabetes experts for patients. The lawsuit alleges that Novo Nordisk attempted to bypass rules established by theU.S. Food and Drug Administration (FDA)regarding promotional materials and communications from sales professionals. The lawsuit said that the value of having a diabetes educator calling on a doctor cannot be understated because they provide materials and education that could cost doctors thousands of dollars. The suit further claims that because the certified diabetes educators were not titled as sales representatives, they received unprecedented access to physicians. However, they were sales representatives in every way except title. Allegedly, the program was meant to induce prescribers to write prescriptions for Novos diabetes medications, and the educators would develop a close bond with doctors (closer than the bond sales representatives can forge) and sales of the drugs were extraordinarily boosted because of the program. Alere Settles False Claims Continue reading >>

Novo Nordisk News & Media - Diabetes Education Program

Novo Nordisk News & Media - Diabetes Education Program

The Novo Nordisk Inc.s Diabetes Education Program is awarded NCQA Disease Management Certification in Program Design. NCQA Certification is an indication that a Disease Management Program has passed a rigorous review in a specific area, either program design or disease management systems. The Diabetes Education Program was evaluated on the following 5 categories: The programs content for educational materials used clinical evidence guidelines The program encourages patient self-management behavior to enable good outcomes The program supports our customers plan of care by providing them with actionable and timely information to support patient needs The program has a quality improvement process in place to evaluate its effectiveness and to identify, measure, and act upon opportunities to improve processes and outcomes The program supports and maintains the operational aspects of the DEP that are important to its success NCQA Disease Management standards are intended to help organizations achieve the highest level of performance possible, reduce patient risk, and create an environment of continuous quality improvement. NCQA Disease Management Certification standards are developed with input from researchers in the field, the Disease Management Advisory Council (DMAC) and standing committee, employers, both purchasers and operators of disease management programs, state and federal regulators, and other experts. Continue reading >>

Did Novo Illegally Use Diabetes Educators To Boost Drug Sales?

Did Novo Illegally Use Diabetes Educators To Boost Drug Sales?

Read more: Price-fixing alleged in lawsuit against insulin makers Sometime between 2006 and 2007, Novo Nordisk entered into an agreement with HealthStar Communications and Practice Therapeutics (a HealthStar entity) to run a program called Changing Life with Diabetes. For this program, Practice Therapeutics hired more than 50 certified diabetes educators (CDEs) to visit physician practices with the stated purpose of providing education about diabetes to physicians, support staff, and patients. According to two CDE whistleblowers and a subsequent investigation, these visits blatantly crossed the line into marketing and sales of Novo Nordisk drugs. There are strict rules surrounding sales calls by pharmaceutical sales representatives, as studies have shown such visits can influence physician prescribing behavior. This lawsuit alleges that Novo Nordisk and the two companies skirted those rules for years by falsely labeling the CDE visits as strictly educational in purpose. The first clue that the program blurred the lines between education and marketing was that the CDEs were trained by Novo Nordisks marketing department, according to lawyers for the states and the whistleblowers. Also, they were not trained in how to provide diabetes education, but in how to market Novo products. The CDEs were allegedly instructed to coordinate closely with Novo sales representatives to gain entry into physician practices and boost prescription numbers of Novo products. Read: The Class-Action Lawsuit Against Novo Nordisk The complaint alleges that the CDEs were given Novo Nordisk branded material to hand out that mentioned Novo Nordisk products by name. They were told to only mention Novo Nordisk products, as well. Their compensation and performance evaluations was tied to how often they Continue reading >>

Novo Nordisk Reaches Whistleblower Settlement In 'white-coat' Sales Scheme Lawsuit

Novo Nordisk Reaches Whistleblower Settlement In 'white-coat' Sales Scheme Lawsuit

Novo Nordisk reaches whistleblower settlement in 'white-coat' sales scheme lawsuit Novo Nordisk reached a settlement deal in a lawsuit alleging the company ran a "white-coat marketing scheme," according to a spokesperson. Novo Nordisk has moved to settle a whistleblower lawsuit alleging the company ran a white-coat marketing scheme to pump up sales of NovoLog, Victoza and Levemir. According to the suit (PDF)recently unsealed as part of the settlement processNovo Nordisk partnered with a clinical education company, Healthstars PT, to set up a program dubbed Changing Life with Diabetes. The group hired and trained certified diabetes educators (CDEs), according to the suit, which was brought by two former managers and more than two dozen states. Like this story? Subscribe to FiercePharma! Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go. The whistleblowers claim that since 2006, Novo ran the program to gain crucial access at physician practices, where CDEs would provide thousands of dollars worth of educational programs and materials. According to the lawsuit, CDEs would provide: Free Novo-branded log books to give to patients; and Unlimited access to Go To diabetes experts for patients. A Novo spokesperson said the drugmaker reached an agreement in principle to settle certain claims related to this investigation. RELATED: Lawmakers suggest Lilly, Novo, Sanofi colluded on insulin prices, call for probe We deny the allegations, and highly value the role our diabetes educators serve in helping HCPs better understand diabetes a Continue reading >>

More in diabetes